DNA topoisomerase I poisons.
作者信息
Takimoto C H, Kieffer L V, Kieffer M E, Arbuck S G, Wright J
机构信息
NCI-Navy Medical Oncology Branch, Naval Hospital Bethesda, MD 20889-5105, USA.
出版信息
Cancer Chemother Biol Response Modif. 1999;18:81-124.
PMID:10800479
Abstract
摘要
相似文献
1
DNA topoisomerase I poisons.
Cancer Chemother Biol Response Modif. 1999;18:81-124.
2
DNA topoisomerase I inhibitors.
Cancer Chemother Biol Response Modif. 1997;17:80-113.
3
An overview of topoisomerase I-targeting agents.
Semin Hematol. 1998 Jul;35(3 Suppl 4):3-12.
4
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):39-46.
5
[Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
Nihon Rinsho. 2003 Sep;61 Suppl 7:472-5.
6
Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Hematol Oncol Clin North Am. 1994 Apr;8(2):333-55.
7
[Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
Bull Cancer. 1998 Dec;Spec No:5-10.
8
Topoisomerase I poisons and suppressors as anticancer drugs.
Curr Med Chem. 2000 Jan;7(1):39-58. doi: 10.2174/0929867003375489.
9
Clinical trials using irinotecan.
J Pediatr Hematol Oncol. 2002 Feb;24(2):84-5. doi: 10.1097/00043426-200202000-00002.
10
p53 and p21 are major cellular determinants for DNA topoisomerase I-mediated radiation sensitization in mammalian cells.
Ann N Y Acad Sci. 2000;922:298-300. doi: 10.1111/j.1749-6632.2000.tb07047.x.
引用本文的文献
1
Pathologies associated with the p53 response.
Cold Spring Harb Perspect Biol. 2010 Jul;2(7):a001180. doi: 10.1101/cshperspect.a001180. Epub 2010 Apr 7.
2
Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons.
J Neurosci. 2003 Sep 17;23(24):8586-95. doi: 10.1523/JNEUROSCI.23-24-08586.2003.
Zotero 插件